Allergy vaccines – new approaches to an old concept

Bibliography

• RING J, KRAMER U, SCHAFER T et al: Why are allergies increasing? Curt Opin. Immunol (2001) 13(6):701–708.
   Web of Science ®Google Scholar
• •An objective discussion of the various hypotheses and forms of evidence as explanations for the present worldwide explosion in allergy.
   Google Scholar
• PORTENGEN L, SIGSGAARD T, OMLAND O, HJORT C, HEEDERIK D, DOEKES G: Low prevalence of atopy in young Danish farmers and farming students born and raised on a farm. Clin. Exp. Allergy (2002) 32(2):247–253.
   PubMed Web of Science ®Google Scholar
• •This paper endorses earlier studies regarding the 'protective effect' of a farm environment for the development of allergies.
   Google Scholar
• MATRICARDI PM, RONCHETTI R: Are infections protecting from atopy? Cult Opin. Allergy Clin. Immunol (2001) 1(5):413–419.
   Google Scholar
• •Provides additional support for the hygiene hypothesis of allergy.
   Google Scholar
• CURTIS HH: The immunising cure of hay fever. Medical News. New York, USA (1900) 77:16.
   Google Scholar
• NOON L: Prophylactic inoculation against hay fever. Lancet (1911) 1:1572.
   Google Scholar
• GLENNY AT, POPE CG, WADDINGTON H et al: The antigenic value of toxoid precipitated by potassium alum.' Path. Bact. (1926) 29:38.
   Google Scholar
• SLEDGE RF: Treatment of hay-fever with alum-precipitated pollen. US Naval Med. Bull. (1938) 36:18.
   Google Scholar
• •The first use of an adjuvant for AV.
   Google Scholar
• WHEELER AW, WORONIECKI SR: Immunological adjuvants in allergy vaccines: past, present and future. Allergol mt. (2001) 50:295–301.
   Google Scholar
• ULANOVA M, TARKOWSKI A, HAHN-ZORIC M et al.: The common vaccine adjuvant aluminium hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Inman. (2001) 69(2):1151–1159.
   PubMed Web of Science ®Google Scholar
• DURHAM SR, TILL SJ: Immunologic changes associated with allergen immunotherapy. I Allergy Clin. Immunol (1998) 102:157–164.
   PubMed Web of Science ®Google Scholar
• ••This paper illustrated the importance of theTh2 to Thl switch in AV.
   Google Scholar
• AKDIS CA, BLASER K: Mechanisms of allergen-specific immunotherapy. Allergy (2000) 55:522–530.
   PubMed Web of Science ®Google Scholar
• MOTHES N, HEINZKILL M, DRACHENBERG KJ et al.: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy (2003) 33:1198–1208.
   PubMed Web of Science ®Google Scholar
• •Resurrection of the blocking antibody theory.
   Google Scholar
• WACHHOLZ PA, DURHAM SR: Induction of 'blocking' IgG antibodies during immunotherapy. Clin. Exp. Allergy (2003) 33:1171–1174.
   PubMed Web of Science ®Google Scholar
• KERSTEN GF, CROMMELIN DJ: Liposomes and ISCOMS. Vaccine (2003) 21(9-10):915–920.
   PubMed Web of Science ®Google Scholar
• ALVAREZ MJ, ECHECHIPIA S, GARCIA B et al.: Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyper responsiveness and immediate and late bronchial responses to the allergen. Clin. Exp. Allergy (2002) 32(11):1574–1582.
   Google Scholar
• SHARIF S, WHEELER AW, O'HAGAN DT: Biodegradable microparticles as a delivery system for the allergens of Dermatophagoides pteronysssinus (house dust mite): 1. Preparation and characterization of microparticles. hat. Pharm. (1995) 119:239–246.
   Google Scholar
• MARSH DG: Preparation and properties of `allergoids' derived from native pollen allergens by mild formalin treatment. Int Arch. Allergy Appl. Immunol (1971) 4(1):199–215.
   Google Scholar
• •The first attempt to produce newer and safer forms of allergens, termed allergoids, by chemical modification.
   Google Scholar
• PATTERSON R, SUSZKO IM, PRUZANSKY JJ et al.: Polymerization of mixtures of grass allergens. Allergy Clio. Immunol (1977) 59(4):314–319.
   PubMed Web of Science ®Google Scholar
• JOHANSSON SG, MILLER AC, MULLAN N, OVERELL BG, TEES EC, WHEELER AW: Glutaraldehyde-pollen-tyrosine: clinical and immunological studies. Clio. Allergy (1974) 4(3):255–263.
   PubMed Web of Science ®Google Scholar
• WESTRITSCHNIG K, VALENTA R: Can we genetically engineer safer and more effective immunotherapy reagents? Curt Opin. Allergy Clio. Immunol (2003) 3(6):495–500.
   Google Scholar
• SWOBODA I, JILEK A, FERREIRA F et al.: Isoforms of Bet v 1, the major birch pollen allergen, analysed by liquid chromatography, mass spectrometry, and cDNA cloning. Biol. Chem (1995) 270(6):2607–2613.
   Web of Science ®Google Scholar
• MAHLER V, VRTLA S, KUSS O et al: Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Clin. Exp. Allergy (2004) 34(1):115–122.
   PubMed Web of Science ®Google Scholar
• •An interesting and scientifically elegant approach to AV.
   Google Scholar
• NORMAN PS, OHMAN JL, LONG AA et al: Treatment of cat allergy with T-cell reactive peptides. Am. I Respir. Crit. Care Med. (1996) 154:1623–1628.
   PubMed Web of Science ®Google Scholar
• •Early studies on peptides for immunotherapy.
   Google Scholar
• LARCHE M: New approaches to immunotherapy: allergen-derived peptides. Immunol Allergy (CPO Bulletin) (2004) 3(3):73–76.
   Google Scholar
• •A short but useful review on T cell-reactive peptides in immunotherapy.
   Google Scholar
• MUELLER U, AKDIS CA, FRICKER M et al.: Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. Allergy Clin. Immunol (1998) 101:747–754.
   Google Scholar
• ••A study supporting the use of non-IgE-reactive T cell epitope-containing peptides for vaccination.
   Google Scholar
• PAZ E, SPIEGELBERG HL: Deviation of the allergic IgE to an IgG response by gene immunotherapy. Lit. Rev. Immunol (1999) 18:271–289.
   Google Scholar
• TIGH H, TAKABAYASHI K, SCHWARTZ D et al: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. I Allergy Clin. Immunol (2000) 106:124–134.
   PubMed Web of Science ®Google Scholar
• KOHAMA Y, AKIZUKI O, HAGIKARI K, YAMADA E, YAMAMOTO H: Immunostimulatory oligodeoxynucleotide induces Thl immune response and inhibition of IgE antibody production to cedar pollen allergens in mice. I Allergy Clin. Immunol (1999) 104:1231–1238.
   PubMed Web of Science ®Google Scholar
• •Interesting studies of the Thl-inducing properties of bacterial ISSs.
   Google Scholar
• WALKER C, SAWICKA E, ROOK GA: Immunotherapy with mycobacteria. Carr. Opin. Allergy Clin. Immunol (2003) 3:481–486.
   PubMed Web of Science ®Google Scholar
• ULRICH JT, MYERS KR: Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Vaccine designs. The sub-unit and adjuvant approach. Powell MF, Mewman MJ (Eds), Plenum Press, New York, USA (1995):495–524.
   Google Scholar
• ••An important review of the production and properties of a clinically acceptable Thl adjuvant.
   Google Scholar
• MARTIN M, MICHALEK SM, KATZ J: Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. (2003) 71(5):2498–2507.
   PubMed Web of Science ®Google Scholar
• •This paper details evidence for cellular mechanisms (including activation of TLR2 and TLR4) by which MPL induces host cell activation.
   Google Scholar
• WHEELER AW, MARSHALL JS, ULRICH JT: A Thl-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol (2001) 126:135–139.
   PubMed Web of Science ®Google Scholar
• •This is an interesting study showing that tyrosine and MPL can act synergistically to produce a Thl response with model antigens.
   Google Scholar
• DRACHENBERG KJ, WHEELER AW, STUEBNER P, HORAK F: A well-tolerated grass pollen specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseason injections. Allergy (2001) 56:498–505.
   PubMed Web of Science ®Google Scholar
• ••A very important clinical study showinghow incorporation of a Thl adjuvant can reduce the number of injections required to obtain efficacy.
   Google Scholar
• DRACHENBERG KJ, HEINZKILL M, URBAN E, WORONIECKI SR: Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvant by monophosphoryl lipid A (MPL®) for children and adolescents. Allergol Immunopathol (2003) 31(5):270–277.
   PubMedGoogle Scholar
• •Confirmation of the efficacy and safety of a Thl adjuvanted allergy vaccine. AV may reduce the progression of allergic disease in children.
   Google Scholar
• MAILLARD I, ADLER SH, PEAR WS: Notch and the immune system. Immunity (2003) 19(6):781–791.
   PubMed Web of Science ®Google Scholar
• ••A novel and very interesting approach tospecific immunomodulation.
   Google Scholar
• BOUSQUET J, LOCKEY FR, MALLING H-J: Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. Allergy (1998) 53:1–42.
   Google Scholar
• ••A landmark paper providing ratification ofAV as a mainstream method of treating allergy.
   Google Scholar
• WILSON DR, TORRES LIMA M, DURHAM SR: Sublingual immunotherapy for allergic rhinitis (Cochrane Review). In: The Cochrane Library issue 2(2003). Oxford: Update software.
   Google Scholar
• •A very thorough statistical analysis of controlled sublingual immunotherapy studies concludes that the treatment may be safe and efficacious.
   Google Scholar
• KLIMEK L, STUCK B, HUNDORF J, SCHNEIDER-GENE S, HORMANN K: Monophosphoryl lipid A (MPL®) has Thl stimulating properties in immunotherapy with birch pollen allergoid. Allergy (2001) 56\(Suppl. 68):93.
   Google Scholar
• •Provides good evidence of MPL inducing a Thl adjuvant effect.
   Google Scholar
• ROVER AC, REIMANN S, ZUBERBIER T, WORM M: Immmunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. I Invest. Allergol Clin. Immunol (2002) 12(4):227–234.
   PubMed Web of Science ®Google Scholar
• •Provides good evidence of MPL inducing a Thl adjuvant effect.
   Google Scholar
• VON BAEHR V, SCHERF HP, HERMES A: Allergoid-specific cellular immune response as a possible marker for immunological M vitro effects of immunotherapy. Allergy (2001) 56\(Suppl. 68):91.
   Google Scholar
• •A publication supporting the use of allergoids, but with rather complex methodology.
   Google Scholar
• PUGGIONI F, FRANCIS JN, DURHAM SR: Monophosphoryl lipid A: M vitro effects on human T cell proliferation and cytokine production. Allergy Clin. Immunol (2003) 111(Pt 2):333.
   Google Scholar
• •Support for Thl adjuvants from a prestigious group. Patent
   Google Scholar
• CARTER EB: Detoxified pollen extract. U52019808 (1935).
   Google Scholar